_id
690da7c3ccc777a4e85d0798
Ticker
AAPG
Name
Ascentage Pharma Group International
Exchange
NASDAQ
Address
Suzhou Industrial Park, Suzhou, China, 215000
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://www.ascentage.cn
Description
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, an orally available and selective embryonic ectoderm development inhibitor. In addition, it is involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and provision of science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.
Last Close
26
Volume
1636
Current Price
25.7
Change
-0.31
Last Updated
2026-01-21T18:07:33.317Z
Image
data:image/webp;base64,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
Ipo Date
2025-01-24T00:00:00.000Z
Market Cap
2433243392
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.29688571428571425
Sentiment Sources
7
Rating
4.5
Target Price
45.7143
Strong Buy
1
Buy
1
Hold
0
Sell
0
Strong Sell
0
Current Quarter
2025-06-30
Revenue
233699000
Cost Of Revenue
21650000
Gross Profit
212049000
Operating Expenses
766033000
Operating Income
-553984000
Interest Expense
-
Pretax Income
-585312000
Net Income
-590768000
Eps
-1.7294599486069053
Dividends Per Share
-
Shares Outstanding
92963369
Income Tax Expense
5512000
EBITDA
-514016499
Operating Margin
-237.05022272239077
Total Other Income Expense Net
-31328000
Cash
1661454000
Short Term Investments
-
Receivables
78362000
Inventories
8591000
Total Current Assets
1908720000
Property Plant Equipment
871961000
Total Assets
3046144000
Payables
118676000
Short Term Debt
833783000
Long Term Debt
882382000
Total Liabilities
2370235000
Equity
665997000
Bs_currency_symbol
CNY
Depreciation
39967501
Change In Working Capital
-
Cash From Operations
-
Capital Expenditures
0
Cash From Investing
-
Cash From Financing
-
Net Change In Cash
-
Cf_currency_symbol
-
PE
-
PB
13.181574982920344
ROE
-88.70430347283846
ROA
-19.393961677451887
FCF
-
Fcf Percent
-
Piotroski FScore
0
Health Score
16
Deep Value Investing Score
3
Defensive Investing Score
5.5
Dividend Investing Score
1.5
Economic Moat Investing Score
2.8
Garp Investing Score
3
Growth Investing Score
3
Momentum Investing Score
3.5
Net Net Investing Score
2
Quality Investing Score
1
Value Investing Score
1.5
Quarters > 0 > quarter
2025-06-30
Quarters > 0 > income Statement > revenue
233699000
Quarters > 0 > income Statement > cost Of Revenue
21650000
Quarters > 0 > income Statement > gross Profit
212049000
Quarters > 0 > income Statement > operating Expenses
766033000
Quarters > 0 > income Statement > operating Income
-553984000
Quarters > 0 > income Statement > interest Expense
-
Quarters > 0 > income Statement > pretax Income
-585312000
Quarters > 0 > income Statement > net Income
-590768000
Quarters > 0 > income Statement > eps
-1.7294599486069053
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
341591027
Quarters > 0 > income Statement > income Tax Expense
5512000
Quarters > 0 > income Statement > EBITDA
-514016499
Quarters > 0 > income Statement > operating Margin
-237.05022272239077
Quarters > 0 > income Statement > total Other Income Expense Net
-31328000
Quarters > 0 > income Statement > currency_symbol
-
Quarters > 0 > balance Sheet > cash
1661454000
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
78362000
Quarters > 0 > balance Sheet > inventories
8591000
Quarters > 0 > balance Sheet > total Current Assets
1908720000
Quarters > 0 > balance Sheet > property Plant Equipment
871961000
Quarters > 0 > balance Sheet > total Assets
3046144000
Quarters > 0 > balance Sheet > payables
118676000
Quarters > 0 > balance Sheet > short Term Debt
833783000
Quarters > 0 > balance Sheet > long Term Debt
882382000
Quarters > 0 > balance Sheet > total Liabilities
2370235000
Quarters > 0 > balance Sheet > equity
665997000
Quarters > 0 > balance Sheet > currency_symbol
CNY
Quarters > 0 > cash Flow > net Income
-1181536000
Quarters > 0 > cash Flow > depreciation
39967501
Quarters > 0 > cash Flow > change In Working Capital
-
Quarters > 0 > cash Flow > cash From Operations
-
Quarters > 0 > cash Flow > capital Expenditures
0
Quarters > 0 > cash Flow > cash From Investing
-
Quarters > 0 > cash Flow > cash From Financing
-
Quarters > 0 > cash Flow > net Change In Cash
-
Quarters > 0 > cash Flow > currency_symbol
-
Quarters > 0 > ratios > PE
-1.7294599486069053
Quarters > 0 > ratios > PB
13.181574982920344
Quarters > 0 > ratios > ROE
-88.70430347283846
Quarters > 0 > ratios > ROA
-19.393961677451887
Quarters > 0 > ratios > FCF
-
Quarters > 0 > ratios > Piotroski FScore
0
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
16
Quarters > 1 > quarter
2025-03-31
Quarters > 1 > income Statement > revenue
156904000
Quarters > 1 > income Statement > cost Of Revenue
14026000
Quarters > 1 > income Statement > gross Profit
142878000
Quarters > 1 > income Statement > operating Expenses
709664000
Quarters > 1 > income Statement > operating Income
-566786000
Quarters > 1 > income Statement > interest Expense
-
Quarters > 1 > income Statement > pretax Income
-558150000
Quarters > 1 > income Statement > net Income
-568434000
Quarters > 1 > income Statement > eps
-1.8197341631132111
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
312372000
Quarters > 1 > income Statement > income Tax Expense
10356000
Quarters > 1 > income Statement > EBITDA
-528454000
Quarters > 1 > income Statement > operating Margin
-361.23107122826696
Quarters > 1 > income Statement > total Other Income Expense Net
8636000
Quarters > 1 > income Statement > currency_symbol
-
Quarters > 1 > balance Sheet > cash
1236578000
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
99074000
Quarters > 1 > balance Sheet > inventories
6597000
Quarters > 1 > balance Sheet > total Current Assets
1474162000
Quarters > 1 > balance Sheet > property Plant Equipment
905860000
Quarters > 1 > balance Sheet > total Assets
2617810000
Quarters > 1 > balance Sheet > payables
91966000
Quarters > 1 > balance Sheet > short Term Debt
779062000
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
2343648000
Quarters > 1 > balance Sheet > equity
264194000
Quarters > 1 > balance Sheet > currency_symbol
-
Quarters > 1 > cash Flow > net Income
-568434000
Quarters > 1 > cash Flow > depreciation
45858000
Quarters > 1 > cash Flow > change In Working Capital
87360000
Quarters > 1 > cash Flow > cash From Operations
243034000
Quarters > 1 > cash Flow > capital Expenditures
7762000
Quarters > 1 > cash Flow > cash From Investing
-230756000
Quarters > 1 > cash Flow > cash From Financing
-82138000
Quarters > 1 > cash Flow > net Change In Cash
-
Quarters > 1 > cash Flow > currency_symbol
-
Quarters > 1 > ratios > PE
-1.8197341631132111
Quarters > 1 > ratios > PB
30.386611353777905
Quarters > 1 > ratios > ROE
-215.15780070705617
Quarters > 1 > ratios > ROA
-21.71410453776248
Quarters > 1 > ratios > FCF
235272000
Quarters > 1 > ratios > Piotroski FScore
2
Quarters > 1 > ratios > fcf Percent
1.4994646407994698
Quarters > 1 > health Score
28
Quarters > 2 > quarter
2024-12-31
Quarters > 2 > income Statement > revenue
156904000
Quarters > 2 > income Statement > cost Of Revenue
14026000
Quarters > 2 > income Statement > gross Profit
142878000
Quarters > 2 > income Statement > operating Expenses
709664000
Quarters > 2 > income Statement > operating Income
-566786000
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
-558150000
Quarters > 2 > income Statement > net Income
-568434000
Quarters > 2 > income Statement > eps
-1.8197341631132111
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
312372000
Quarters > 2 > income Statement > income Tax Expense
10356000
Quarters > 2 > income Statement > EBITDA
-528454000
Quarters > 2 > income Statement > operating Margin
-361.23107122826696
Quarters > 2 > income Statement > total Other Income Expense Net
8636000
Quarters > 2 > income Statement > currency_symbol
-
Quarters > 2 > balance Sheet > cash
1236578000
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
99074000
Quarters > 2 > balance Sheet > inventories
6597000
Quarters > 2 > balance Sheet > total Current Assets
1474162000
Quarters > 2 > balance Sheet > property Plant Equipment
905860000
Quarters > 2 > balance Sheet > total Assets
2617810000
Quarters > 2 > balance Sheet > payables
91966000
Quarters > 2 > balance Sheet > short Term Debt
779062000
Quarters > 2 > balance Sheet > long Term Debt
868642000
Quarters > 2 > balance Sheet > total Liabilities
2343648000
Quarters > 2 > balance Sheet > equity
264194000
Quarters > 2 > balance Sheet > currency_symbol
CNY
Quarters > 2 > cash Flow > net Income
-568434000
Quarters > 2 > cash Flow > depreciation
45858000
Quarters > 2 > cash Flow > change In Working Capital
87360000
Quarters > 2 > cash Flow > cash From Operations
243034000
Quarters > 2 > cash Flow > capital Expenditures
7762000
Quarters > 2 > cash Flow > cash From Investing
-230756000
Quarters > 2 > cash Flow > cash From Financing
-82138000
Quarters > 2 > cash Flow > net Change In Cash
-
Quarters > 2 > cash Flow > currency_symbol
-
Quarters > 2 > ratios > PE
-1.8197341631132111
Quarters > 2 > ratios > PB
30.386611353777905
Quarters > 2 > ratios > ROE
-215.15780070705617
Quarters > 2 > ratios > ROA
-21.71410453776248
Quarters > 2 > ratios > FCF
235272000
Quarters > 2 > ratios > Piotroski FScore
2
Quarters > 2 > ratios > fcf Percent
1.4994646407994698
Quarters > 2 > health Score
28
Quarters > 3 > quarter
2024-09-30
Quarters > 3 > income Statement > revenue
78452000
Quarters > 3 > income Statement > cost Of Revenue
7013000
Quarters > 3 > income Statement > gross Profit
71439000
Quarters > 3 > income Statement > operating Expenses
354832000
Quarters > 3 > income Statement > operating Income
-283393000
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-279075000
Quarters > 3 > income Statement > net Income
-284217000
Quarters > 3 > income Statement > eps
-0.9098670815566056
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
312372000
Quarters > 3 > income Statement > income Tax Expense
5178000
Quarters > 3 > income Statement > EBITDA
-264227000
Quarters > 3 > income Statement > operating Margin
-361.23107122826696
Quarters > 3 > income Statement > total Other Income Expense Net
4318000
Quarters > 3 > income Statement > currency_symbol
-
Quarters > 3 > balance Sheet > cash
1261211000
Quarters > 3 > balance Sheet > short Term Investments
5367000
Quarters > 3 > balance Sheet > receivables
83143000
Quarters > 3 > balance Sheet > inventories
6597000
Quarters > 3 > balance Sheet > total Current Assets
1474162000
Quarters > 3 > balance Sheet > property Plant Equipment
905559000
Quarters > 3 > balance Sheet > total Assets
2617810000
Quarters > 3 > balance Sheet > payables
91966000
Quarters > 3 > balance Sheet > short Term Debt
779062000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
2343648000
Quarters > 3 > balance Sheet > equity
264194000
Quarters > 3 > balance Sheet > currency_symbol
-
Quarters > 3 > cash Flow > net Income
-284217000
Quarters > 3 > cash Flow > depreciation
22929000
Quarters > 3 > cash Flow > change In Working Capital
43680000
Quarters > 3 > cash Flow > cash From Operations
121517000
Quarters > 3 > cash Flow > capital Expenditures
3881000
Quarters > 3 > cash Flow > cash From Investing
-115378000
Quarters > 3 > cash Flow > cash From Financing
-41069000
Quarters > 3 > cash Flow > net Change In Cash
-
Quarters > 3 > cash Flow > currency_symbol
-
Quarters > 3 > ratios > PE
-0.9098670815566056
Quarters > 3 > ratios > PB
30.386611353777905
Quarters > 3 > ratios > ROE
-107.57890035352808
Quarters > 3 > ratios > ROA
-10.85705226888124
Quarters > 3 > ratios > FCF
117636000
Quarters > 3 > ratios > Piotroski FScore
2
Quarters > 3 > ratios > fcf Percent
1.4994646407994698
Quarters > 3 > health Score
28
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
980650000
Annuals > 0 > income Statement > cost Of Revenue
29085000
Annuals > 0 > income Statement > gross Profit
951565000
Annuals > 0 > income Statement > operating Expenses
1321295000
Annuals > 0 > income Statement > operating Income
-369730000
Annuals > 0 > income Statement > interest Expense
64455000
Annuals > 0 > income Statement > pretax Income
-395255000
Annuals > 0 > income Statement > net Income
-405433000
Annuals > 0 > income Statement > eps
-1.3422178228310744
Annuals > 0 > income Statement > dividends Per Share
0
Annuals > 0 > income Statement > shares Outstanding
302062000
Annuals > 0 > income Statement > income Tax Expense
10425000
Annuals > 0 > income Statement > EBITDA
-237631000
Annuals > 0 > income Statement > operating Margin
-37.70254423086728
Annuals > 0 > income Statement > total Other Income Expense Net
-25525000
Annuals > 0 > income Statement > currency_symbol
CNY
Annuals > 0 > balance Sheet > cash
1236578000
Annuals > 0 > balance Sheet > short Term Investments
5367000
Annuals > 0 > balance Sheet > receivables
99074000
Annuals > 0 > balance Sheet > inventories
6597000
Annuals > 0 > balance Sheet > total Current Assets
1474162000
Annuals > 0 > balance Sheet > property Plant Equipment
905860000
Annuals > 0 > balance Sheet > total Assets
2617810000
Annuals > 0 > balance Sheet > payables
91966000
Annuals > 0 > balance Sheet > short Term Debt
779062000
Annuals > 0 > balance Sheet > long Term Debt
868642000
Annuals > 0 > balance Sheet > total Liabilities
2343648000
Annuals > 0 > balance Sheet > equity
264194000
Annuals > 0 > balance Sheet > currency_symbol
CNY
Annuals > 0 > cash Flow > net Income
-395255000
Annuals > 0 > cash Flow > depreciation
93169000
Annuals > 0 > cash Flow > change In Working Capital
110966000
Annuals > 0 > cash Flow > cash From Operations
-111357000
Annuals > 0 > cash Flow > capital Expenditures
24289000
Annuals > 0 > cash Flow > cash From Investing
-362035000
Annuals > 0 > cash Flow > cash From Financing
314767000
Annuals > 0 > cash Flow > net Change In Cash
-144948000
Annuals > 0 > cash Flow > currency_symbol
CNY
Annuals > 0 > ratios > PE
-1.3422178228310744
Annuals > 0 > ratios > PB
29.383685473553523
Annuals > 0 > ratios > ROE
-153.46033596523768
Annuals > 0 > ratios > ROA
-15.487487632792297
Annuals > 0 > ratios > FCF
-135646000
Annuals > 0 > ratios > Piotroski FScore
0
Annuals > 0 > ratios > fcf Percent
-0.13832254117167184
Annuals > 0 > health Score
8
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
221984000
Annuals > 1 > income Statement > cost Of Revenue
30543000
Annuals > 1 > income Statement > gross Profit
191441000
Annuals > 1 > income Statement > operating Expenses
1064077000
Annuals > 1 > income Statement > operating Income
-872636000
Annuals > 1 > income Statement > interest Expense
96057000
Annuals > 1 > income Statement > pretax Income
-932862000
Annuals > 1 > income Statement > net Income
-925637000
Annuals > 1 > income Statement > eps
-13.11568402649914
Annuals > 1 > income Statement > dividends Per Share
0
Annuals > 1 > income Statement > shares Outstanding
70574817
Annuals > 1 > income Statement > income Tax Expense
-7150000
Annuals > 1 > income Statement > EBITDA
-743610000
Annuals > 1 > income Statement > operating Margin
-393.10761135937724
Annuals > 1 > income Statement > total Other Income Expense Net
-60226000
Annuals > 1 > income Statement > currency_symbol
USD
Annuals > 1 > balance Sheet > cash
1069296000
Annuals > 1 > balance Sheet > short Term Investments
4405967
Annuals > 1 > balance Sheet > receivables
163540000
Annuals > 1 > balance Sheet > inventories
16167000
Annuals > 1 > balance Sheet > total Current Assets
1344178000
Annuals > 1 > balance Sheet > property Plant Equipment
957232000
Annuals > 1 > balance Sheet > total Assets
2500393000
Annuals > 1 > balance Sheet > payables
72445000
Annuals > 1 > balance Sheet > short Term Debt
616404000
Annuals > 1 > balance Sheet > long Term Debt
1166267000
Annuals > 1 > balance Sheet > total Liabilities
2429761000
Annuals > 1 > balance Sheet > equity
60417000
Annuals > 1 > balance Sheet > currency_symbol
CNY
Annuals > 1 > cash Flow > net Income
-932862000
Annuals > 1 > cash Flow > depreciation
93195000
Annuals > 1 > cash Flow > change In Working Capital
-9146000
Annuals > 1 > cash Flow > cash From Operations
-726077000
Annuals > 1 > cash Flow > capital Expenditures
56844000
Annuals > 1 > cash Flow > cash From Investing
21922000
Annuals > 1 > cash Flow > cash From Financing
368751000
Annuals > 1 > cash Flow > net Change In Cash
-307591000
Annuals > 1 > cash Flow > currency_symbol
CNY
Annuals > 1 > ratios > PE
-13.11568402649914
Annuals > 1 > ratios > PB
30.020901350613237
Annuals > 1 > ratios > ROE
-1532.080374728967
Annuals > 1 > ratios > ROA
-37.01966050936793
Annuals > 1 > ratios > FCF
-782921000
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-3.5269253639901974
Annuals > 1 > health Score
8
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
209711000
Annuals > 2 > income Statement > cost Of Revenue
21998000
Annuals > 2 > income Statement > gross Profit
187713000
Annuals > 2 > income Statement > operating Expenses
1037523000
Annuals > 2 > income Statement > operating Income
-849810000
Annuals > 2 > income Statement > interest Expense
52785000
Annuals > 2 > income Statement > pretax Income
-887172000
Annuals > 2 > income Statement > net Income
-882924000
Annuals > 2 > income Statement > eps
-13.394439078622355
Annuals > 2 > income Statement > dividends Per Share
0
Annuals > 2 > income Statement > shares Outstanding
65917206
Annuals > 2 > income Statement > income Tax Expense
-4248000
Annuals > 2 > income Statement > EBITDA
-786966000
Annuals > 2 > income Statement > operating Margin
-405.22910100090127
Annuals > 2 > income Statement > total Other Income Expense Net
-37362000
Annuals > 2 > income Statement > currency_symbol
USD
Annuals > 2 > balance Sheet > cash
1475639000
Annuals > 2 > balance Sheet > short Term Investments
18700461
Annuals > 2 > balance Sheet > receivables
61489000
Annuals > 2 > balance Sheet > inventories
9448000
Annuals > 2 > balance Sheet > total Current Assets
1636488000
Annuals > 2 > balance Sheet > property Plant Equipment
650025000
Annuals > 2 > balance Sheet > total Assets
2830261000
Annuals > 2 > balance Sheet > payables
95559000
Annuals > 2 > balance Sheet > short Term Debt
518383000
Annuals > 2 > balance Sheet > long Term Debt
1265200000
Annuals > 2 > balance Sheet > total Liabilities
2421603000
Annuals > 2 > balance Sheet > equity
408658000
Annuals > 2 > balance Sheet > currency_symbol
CNY
Annuals > 2 > cash Flow > net Income
-887172000
Annuals > 2 > cash Flow > depreciation
62915000
Annuals > 2 > cash Flow > change In Working Capital
104413000
Annuals > 2 > cash Flow > cash From Operations
-653915000
Annuals > 2 > cash Flow > capital Expenditures
236963000
Annuals > 2 > cash Flow > cash From Investing
-384612000
Annuals > 2 > cash Flow > cash From Financing
619268000
Annuals > 2 > cash Flow > net Change In Cash
-361247000
Annuals > 2 > cash Flow > currency_symbol
CNY
Annuals > 2 > ratios > PE
-13.394439078622355
Annuals > 2 > ratios > PB
4.145452173210851
Annuals > 2 > ratios > ROE
-216.05450034013774
Annuals > 2 > ratios > ROA
-31.195850842024818
Annuals > 2 > ratios > FCF
-890878000
Annuals > 2 > ratios > Piotroski FScore
0
Annuals > 2 > ratios > fcf Percent
-4.2481224160869
Annuals > 2 > health Score
11
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
27910000
Annuals > 3 > income Statement > cost Of Revenue
3328000
Annuals > 3 > income Statement > gross Profit
24582000
Annuals > 3 > income Statement > operating Expenses
894417000
Annuals > 3 > income Statement > operating Income
-869835000
Annuals > 3 > income Statement > interest Expense
16731000
Annuals > 3 > income Statement > pretax Income
-832249000
Annuals > 3 > income Statement > net Income
-782424000
Annuals > 3 > income Statement > eps
-12.291860521197233
Annuals > 3 > income Statement > dividends Per Share
0
Annuals > 3 > income Statement > shares Outstanding
63653830
Annuals > 3 > income Statement > income Tax Expense
-49825000
Annuals > 3 > income Statement > EBITDA
-798335000
Annuals > 3 > income Statement > operating Margin
-3116.5711214618414
Annuals > 3 > income Statement > total Other Income Expense Net
37586000
Annuals > 3 > income Statement > currency_symbol
USD
Annuals > 3 > balance Sheet > cash
1706886000
Annuals > 3 > balance Sheet > short Term Investments
-
Annuals > 3 > balance Sheet > receivables
54127000
Annuals > 3 > balance Sheet > inventories
3930000
Annuals > 3 > balance Sheet > total Current Assets
1885280000
Annuals > 3 > balance Sheet > property Plant Equipment
854302000
Annuals > 3 > balance Sheet > total Assets
2940060000
Annuals > 3 > balance Sheet > payables
70861000
Annuals > 3 > balance Sheet > short Term Debt
49451000
Annuals > 3 > balance Sheet > long Term Debt
1026592000
Annuals > 3 > balance Sheet > total Liabilities
1705323000
Annuals > 3 > balance Sheet > equity
1234737000
Annuals > 3 > balance Sheet > currency_symbol
CNY
Annuals > 3 > cash Flow > net Income
-832249000
Annuals > 3 > cash Flow > depreciation
28326000
Annuals > 3 > cash Flow > change In Working Capital
-74911000
Annuals > 3 > cash Flow > cash From Operations
-604679000
Annuals > 3 > cash Flow > capital Expenditures
436629000
Annuals > 3 > cash Flow > cash From Investing
-466522000
Annuals > 3 > cash Flow > cash From Financing
1781387000
Annuals > 3 > cash Flow > net Change In Cash
686907000
Annuals > 3 > cash Flow > currency_symbol
CNY
Annuals > 3 > ratios > PE
-12.291860521197233
Annuals > 3 > ratios > PB
1.3249003075148797
Annuals > 3 > ratios > ROE
-63.36766453098919
Annuals > 3 > ratios > ROA
-26.612518111875268
Annuals > 3 > ratios > FCF
-1041308000
Annuals > 3 > ratios > Piotroski FScore
0
Annuals > 3 > ratios > fcf Percent
-37.30949480472949
Annuals > 3 > health Score
24
Valuation > metrics > PE
-1.7294599486069053
Valuation > metrics > PB
13.181574982920344
Valuation > final Score
20
Valuation > verdict
339.4% Overvalued
Profitability > metrics > ROE
-88.70430347283846
Profitability > metrics > ROA
-30.95100381407435
Profitability > metrics > Net Margin
-2.5279012747166227
Profitability > final Score
0
Profitability > verdict
Weak
Risk > metrics > Debt Equity
3.558927442616108
Risk > metrics > Interest Coverage
-7.7702518704511245
Risk > final Score
-25
Risk > verdict
High
Liquidity > metrics > Current Ratio
-
Liquidity > metrics > Quick Ratio
-
Liquidity > final Score
50
Liquidity > verdict
Weak
Prev Valuations > 0
20
Prev Valuations > 1
20
Prev Valuations > 2
20
Prev Profitabilities > 0
0
Prev Profitabilities > 1
0
Prev Profitabilities > 2
0
Prev Risks > 0
-70
Prev Risks > 1
-70
Prev Risks > 2
-70
Prev Liquidities > 0
50
Prev Liquidities > 1
50
Prev Liquidities > 2
50
Updated At
2026-01-21T18:07:34.005Z
Earnings History > 0 > period
2025-12-31
Earnings History > 0 > report Date
2026-03-26
Earnings History > 0 > date
2025-12-31
Earnings History > 0 > before After Market
AfterMarket
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-
Earnings History > 0 > eps Estimate
-
Earnings History > 0 > eps Difference
0
Earnings History > 0 > surprise Percent
-
Earnings History > 1 > period
2025-06-30
Earnings History > 1 > report Date
2025-08-07
Earnings History > 1 > date
2025-06-30
Earnings History > 1 > before After Market
-
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
-1.73
Earnings History > 1 > eps Estimate
0
Earnings History > 1 > eps Difference
-1.73
Earnings History > 1 > surprise Percent
-
Earnings History > 2 > period
2025-03-31
Earnings History > 2 > report Date
2025-04-16
Earnings History > 2 > date
2025-03-31
Earnings History > 2 > before After Market
-
Earnings History > 2 > currency
-
Earnings History > 2 > eps Actual
-1.82
Earnings History > 2 > eps Estimate
0
Earnings History > 2 > eps Difference
-1.82
Earnings History > 2 > surprise Percent
-
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, an orally available and selective embryonic ectoderm development inhibitor. In addition, it is involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and provision of science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.
Stock Price
$0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AAug Intraday: Whats the beta of LXPPRC stock - Trade Risk Report & Free Risk Controlled Daily Trade Plans baoquankhu1.vn
Read more →Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Down - What's Next? - MarketBeat
1/21/2026
Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Down - What's Next? MarketBeat
Read more →Showing 2 of 10
(Last Updated 2025-06-30)
Rating:
STRONG BUY
Target Price:
$45.7143
Analyst Picks
Strong Buy
1
Buy
1
Hold
0
Sell
0
Strong Sell
0
Sentiment:
Neutral
(Last Updated 2025-06-30)
Health Score
Price to Book Ratio (P/B)
-
Very High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Debt to Equity
-
Very Low
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of Ascentage Pharma Group International
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
2025-12-31
EPS Estimate
—
Date
2025-06-30
EPS Actual
-1.73
EPS Estimate
0
EPS Difference
-1.73
Surprise Percent
0%
(Last Updated 2025-06-30)
(Last Updated 2025-06-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-06-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-06-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.